Andrew N. Freedman, Ph.D.
Branch Chief, Clinical and Translational Epidemiology Branch
- Telephone: (240) 276-6697
- Fax: (240) 276-7920
- E-mail: firstname.lastname@example.org
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E226, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
- Developing, applying, and evaluating prediction models for cancer risk and prognosis
- Developing benefit/risk indices for pharmaceuticals used to prevent and treat cancer
- Identifying clinical, epidemiologic, and pharmacogenomic factors related to cancer treatment outcomes
- Ph.D. - Experimental Pathology/Epidemiology
University of Buffalo and Roswell Park Cancer Institute
- M.S. - Epidemiology
University of Buffalo
- B.S. - Biology
University of Buffalo
Dr. Freedman is the Chief of the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). He oversees EGRP's research portfolio and initiatives that focus on factors that influence cancer progression, recurrence, new primary cancers, survival and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions.
In 1997, Dr. Freedman joined NCI's Division of Cancer Control and Population Sciences (DCCPS) as a molecular epidemiologist in the Applied Research Program's (ARP) Risk Factor Monitoring and Methods Branch. He developed and supported a program of research in cancer risk prediction, genetic susceptibility testing, pharmacoepidemiology and pharmacogenomics, and managed research contracts, interagency and cooperative agreements, and a grant portfolio pertaining to these research areas. Dr. Freedman also directed multidisciplinary molecular, clinical, and translational epidemiology studies within the HMO Cancer Research Network (CRN); Department of Veterans Affairs medical system; NCI's Surveillance, Epidemiology, and End Results (SEER) Program; and the NIH-AARP Diet and Health Study. He is internationally recognized for his work in molecular cancer epidemiology and cancer risk prediction.
In the areas of pharmacoepidemiology and pharmacogenomics, Dr. Freedman has developed research collaborations with several NIH Institutes and Centers and other agencies within the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA). He is Chair of the Trans-NCI Pharmacoepidemiology and Pharmacogenomics Working Group, and represents NCI on the Trans-NIH Pharmacogenomics Working Group and the Institute of Medicine (IOM) Roundtable on Translating Genomic-Based Research for Health. Before joining DCCPS, Dr. Freedman was a Postdoctoral Research Fellow in the Genetic Epidemiology Branch of NCI's Division of Cancer Epidemiology and Genetics (DCEG).